BRKRHIGH SIGNALFINANCIAL10-K

BRKR experienced massive revenue growth of 306% to $1.9B but suffered a dramatic profitability collapse, swinging from $113M net income to an $8.6M loss.

This represents a classic growth-at-any-cost scenario where the company appears to have scaled rapidly but at the expense of operational efficiency and profitability. The 73% decline in operating income despite tripling revenue suggests significant margin compression, integration challenges, or unsustainable pricing strategies that investors should scrutinize closely.

Comparing 2026-02-27 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

BRKR's financial profile transformed dramatically with revenue exploding 306% to $1.9B while profitability completely evaporated, moving from $113M net income to an $8.6M loss and operating income plummeting 73%. Despite the revenue surge, operating cash flow declined 47% to $134M, indicating the growth may not be generating sustainable cash returns. The company strengthened its balance sheet with 63% higher cash reserves and 38% growth in stockholders' equity while reducing debt 11%, suggesting they raised capital to fund this aggressive expansion but at the cost of near-term profitability.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+306.3%
$466.6M$1.9B

Strong top-line growth of 306.3% — accelerating demand or successful expansion into new markets.

Net Income
P&L
-107.6%
$113.1M-$8.6M

Net income declined 107.6% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-73.1%
$253.1M$68.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
+62.9%
$183.4M$298.8M

Cash position surged 62.9% — strong cash generation or capital raise providing significant financial cushion.

Operating Cash Flow
Cash Flow
-46.6%
$251.3M$134.1M

Operating cash flow fell 46.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
+37.9%
$1.8B$2.5B

Equity base grew 37.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Capital Expenditure
Cash Flow
-21.2%
$115.3M$90.8M

Capex reduced 21.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Debt
Balance Sheet
-10.8%
$2.1B$1.9B

Debt reduced 10.8% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-03
ADDED
As of February 20, 2026, there were 152,219,250 of the registrant s common stock outstanding and 2,760,000 of the registrant s Series A mandatory convertible preferred stock outstanding.
Business Segments We have four reportable segments, Bruker Scientific Instruments ( BSI ) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI NANO, and Bruker Energy Supercon Technologies ( BEST ), which each comprise several divisions as disclosed below.
It offers comprehensive software solutions for workflow integration, automation, and artificial intelligence readiness, adhering to Findability, Accessibility, Interoperability, and Reusability ( FAIR ) data principles.
During 2025, we continued our focus on enhancing customer relationships and driving innovation with our key initiatives, which include expanding into high-potential markets, leveraging core strengths, and driving recurring revenue through aftermarket and connected services.
Furthermore, during 2025, we completed certain minority investments which align with the segment s goals of expanding its technological capabilities, entering new markets, and enhancing its product portfolio.
+7 more — sign up free →
REMOVED
Our principal executive offices are located at 40 Manning Road, Billerica, MA 01821, and our telephone number is (978) 663-3660.
Business Segments We have four reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI NANO, and Bruker Energy Supercon Technologies (BEST).
Furthermore, BSI BioSpin s product enables the characterization of mixtures and also complex materials, rendering them high value-added tools for a variety of industrial applications.
It offers comprehensive software solutions for workflow integration, automation, and artificial intelligence readiness, adhering to Findability, Accessibility, Interoperability, and Reusability (FAIR) data principles.
Automation: Provides solutions for lab automation and digitalization in Research Development and Quality Control.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →